Acadia Pharmaceuticals (ACAD) EBIT Margin (2010 - 2026)

Acadia Pharmaceuticals' EBIT Margin history runs 17 years deep, the most recent figure standing at 1.72% for Q1 2026.

• On a quarterly basis, EBIT Margin fell 962.0% year-over-year to 1.72% in Q1 2026; TTM through Mar 2026 was 7.39%, a 1619.0% decrease from a year earlier, with the FY2025 full-year figure at 9.78%, down 1431.0% from the prior year.
• EBIT Margin eased to 1.72% in Q1 2026 per ACAD's latest filing, from 6.12% in the prior quarter.
• Across five years, EBIT Margin topped out at 59.13% in Q4 2024 and bottomed at 97.88% in Q1 2022.
• The 5-year median for EBIT Margin is 6.12% (2025), against an average of 6.28%.
• Across the five-year window, EBIT Margin surged 5264 bps in 2023 and slumped 5301 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 33.75% in 2022, then surged by 145 bps to 15.12% in 2023, then soared by 291 bps to 59.13% in 2024, then plunged by 90 bps to 6.12% in 2025, then plunged by 128 bps to 1.72% in 2026.
• Per Business Quant, the three latest ACAD EBIT Margin figures stand at 1.72% (Q1 2026), 6.12% (Q4 2025), and 12.83% (Q3 2025).